CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.

BACKGROUND & AIMS Anti-tumor immunity changes over the course of tumor progression; it is not clear how or when the developing tumor overcomes immune surveillance. Intraductal papillary mucinous neoplasm (IPMN) is an intraepithelial precursor lesion of pancreatic cancer that progresses from adenoma to carcinoma. We investigated when and how the human anti-tumor immune reaction changes during pancreatic tumor development. METHODS Using immunohistochemical analysis of cells isolated from patients with IPMN, the numbers of tumor-infiltrating lymphocytes and dendritic cells and the maturation state of dendritic cells in the regional lymph nodes were investigated during tumor progression. Gene expression profiles were compared among epithelial neoplastic cells at each stage of tumor development. Biological functions of the selected gene products were analyzed using syngeneic mouse models. RESULTS The anti-tumor immune reaction changed from an immune response to immune tolerance between the stages of intraductal papillary mucinous adenoma (IPMA) and intraductal papillary mucinous carcinoma (IPMC). Chemokine (C-X-C motif) ligand 17 (CXCL17) and intercellular adhesion molecule 2 (ICAM2) were involved in immune surveillance during tumor development-their expression levels were up-regulated exclusively in IPMA and disappeared from IPMC. CXCL17 and ICAM2 induced infiltration and accumulation of the tumor epithelial layer by immature myeloid dendritic cells. This was followed by a cellular immune reaction and ICAM2 simultaneously promoted the susceptibility of the tumor cells to cytotoxic T-cell-mediated cytolysis. These processes had a synergistic effect to increase the anti-tumor immune response. CONCLUSIONS Immune surveillance occurs during the early intraepithelial stages of human pancreatic carcinogenesis and is mediated by expression of CXCL17 and ICAM2.

[1]  P. Delvenne,et al.  Defensins induce the recruitment of dendritic cells in cervical human papillomavirus‐associated (pre)neoplastic lesions formed in vitro and transplanted in vivo , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Jia-huai Wang,et al.  Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses , 1998, Immunological reviews.

[3]  Yong‐jun Liu,et al.  Development of dendritic-cell lineages. , 2007, Immunity.

[4]  S. Hirohashi,et al.  Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Scarpa,et al.  Pathology and Genetics , 2010 .

[6]  L. Old,et al.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. , 2006, The Journal of clinical investigation.

[7]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[8]  M. Smyth,et al.  NKG2D and cytotoxic effector function in tumor immune surveillance. , 2006, Seminars in immunology.

[9]  R. Ferris,et al.  Loss of New Chemokine CXCL14 in Tumor Tissue Is Associated with Low Infiltration by Dendritic Cells (DC), while Restoration of Human CXCL14 Expression in Tumor Cells Causes Attraction of DC Both In Vitro and In Vivo1 , 2005, The Journal of Immunology.

[10]  M. Mori,et al.  Immunohistochemical evaluation of squamous cell carcinoma antigen and s‐100 protein‐positive cells in human malignant esophageal tissues , 1990, Cancer.

[11]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[12]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[13]  D. Klimstra,et al.  Intraductal papillary‐mucinous neoplasms of the pancreas , 2002, Cancer.

[14]  R. Hruban,et al.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study , 2005, Virchows Archiv.

[15]  S. Tsuboi,et al.  A novel, high endothelial venule-specific sulfotransferase expresses 6-sulfo sialyl Lewis(x), an L-selectin ligand displayed by CD34. , 1999, Immunity.

[16]  Michio Shimizu,et al.  An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms , 2004, The American journal of surgical pathology.

[17]  K. Rückert,et al.  [Classification of pancreatic cancer]. , 1985, Deutsche medizinische Wochenschrift.

[18]  G. Frantz,et al.  Cutting Edge: Novel Human Dendritic Cell- and Monocyte-Attracting Chemokine-Like Protein Identified by Fold Recognition Methods , 2006, The Journal of Immunology.

[19]  M. Lotze,et al.  Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 , 2009, Proceedings of the National Academy of Sciences.

[20]  R. Johnstone,et al.  From cancer immunosurveillance to cancer immunotherapy , 2007, Immunological reviews.

[21]  D. Longnecker.  Intraductal papillary-mucinous neoplasms of the pancreas , 2000 .

[22]  貞苅 良彦.  Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules , 2010 .

[23]  M. Mori,et al.  S‐100 protein‐positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis , 1989, Cancer.

[24]  M. Shimaoka,et al.  Conformational regulation of integrin structure and function. , 2002, Annual review of biophysics and biomolecular structure.

[25]  F. Geissmann,et al.  Transforming Growth Factor (cid:98) 1, in the Presence of Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood Monocytes into Dendritic Langerhans Cells , 2022 .

[26]  A. Hall,et al.  Epithelial ICAM-1 and ICAM-2 regulate the egression of human T cells across the bronchial epithelium , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  E. Berg,et al.  α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 , 1993, Cell.

[28]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[29]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[30]  折茂 達也.  Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma , 2009 .

[31]  Y. Kanai,et al.  Minimally Invasive Intraductal Papillary-mucinous Carcinoma of the Pancreas: Clinicopathologic Study of 104 Intraductal Papillary-mucinous Neoplasms , 2008, The American journal of surgical pathology.

[32]  S. Chari,et al.  International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas , 2006, Pancreatology.

[33]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[34]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[35]  T. Hibi,et al.  Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility , 2009, Laboratory Investigation.

[36]  D. Shelton,et al.  Microarray analysis of replicative senescence , 1999, Current Biology.

[37]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[38]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[39]  L. Old,et al.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.

[40]  Carl G. Figdor,et al.  DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking , 2000, Nature Immunology.

[41]  M. Dhodapkar,et al.  Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy , 2003, The Journal of experimental medicine.